アーデリックス - 関連ニュース

NewsNewsfile Corp

ROSEN, LEADING INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

New York, New York--(Newsfile Corp. - September 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ardelyx,

21 hours ago

NewsPRNewsWire

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) bet

3 days ago

EarningsMarketBeat

Ardelyx Targets $500M Revenue This Year, Profitability by 2027

Ardelyx NASDAQ: ARDX expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia

3 days ago

OtherPRNewsWire

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 /PRNewswir

last month

EarningsSeeking Alpha

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA a

last month